TG Therapeutics shares made new 52-week highs this week, helped in part by new Briumvi data presentations at ECTRIMS. Find ...

We recently compiled a list of the 14 Worst 52-Week High Stocks to Buy According to Short Sellers. In this article, we are ...

Most readers would already be aware that TG Therapeutics' (NASDAQ:TGTX) stock increased significantly by 49% over ...

TG Therapeutics (TGTX) In a report released yesterday ... In a report issued on September 4, Raymond James also maintained a Buy rating on the stock with a $94.00 price target. Boston Scientific ...

During the last three months, 4 analysts shared their evaluations of TG Therapeutics TGTX, revealing diverse outlooks from ...

TG Therapeutics (TGTX) presented updated data from the ENHANCE Phase 3b trial evaluating BRIUMVI in patients with relapsing forms of ...

The data showed that continued use of BRIUMVI resulted in an annualized relapse rate of 2% at year five. TG Therapeutics, Inc. TGTX stock is trading higher on Wednesday after the company announced it ...

As of the latest trading close, TGTX, a Healthcare sector stock, is trading -3.15% below its 52-week high but remains 285.29% above its 52-week low. The Average True Range (ATR) (14 days) of 1.42 ...

As of 03:52PM EDT. Market open. S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on ...

As of 13 September at 12:40 pm GMT-4. Market open. Adjusted closing price adjusted for splits and dividend and/or capital gain distributions.

TG Therapeutics Inc common stock (TGTX) stock saw a modest uptick, ending the day at $23.19 which represents a slight increase of $0.12 or 0.52% from the prior close of $23.07. The stock opened at $22 ...

Check the time stamp on this data. Updated AI-Generated Signals for Tg Therapeutics Inc. (TGTX) available here: TGTX.